Continuous daily dosing of sunitinib in patients with metastatic renal cell cancer

Onkologie

Volumn 31, Issue 8-9, 2008, Pages 432-433

  Harshman, Lauren ^a   Srinivas, Sandy ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; DRUG METABOLITE; SU 012662; SUNITINIB; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; ASTHENIA; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INTERMITTENT THERAPY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; EDITORIAL; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPOTHYROIDISM; KIDNEY CANCER; KIDNEY CARCINOMA; LETHARGY; METASTASIS; MUCOSA INFLAMMATION; MUSCLE HYPERTONIA; REBOUND; TREATMENT RESPONSE; WEAKNESS;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; INDOLES; KIDNEY NEOPLASMS; PYRROLES; TREATMENT OUTCOME;

EID: 52249083726     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000144179     Document Type: Editorial

References (12)

1. Kahl C HI, Freund M, Casper J: Continuous therapy of sunitinib in patients with metastatic renal cell carcinoma. Onkologie 2008;31:485.
2. Mendel DB, Laird AD, Xin X, et al.: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9:327-37.
3. Motzer RJ, Hutson TE, Tomczak P, et al.: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24.
4. Figlin RA HT, Tomczak P, Michaelson MD, Bukowski RM, Negrier S, Huang X, Kim ST, Chen I, Motzer RJ: Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC). ASCO Annual Meeting Proceedings 2008; Abstr 5024.
5. Faivre S, Delbaldo C, Vera K, et al.: Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006;24:25-35.
6. Chow LQ, Eckhardt SG: Sunitinib: from rational design to clinical efficacy. J Clin Oncol 2007;25:884-96.
7. Raymond E FS, Vera K, Delbaldo C, Robert C, Spatz A, Bello C, Brega N, Scigalla P, Armand JP: Final results of a phase I and pharmacokinetic study of SU11248, a novel multi-target tyrosine kinase inhibitor, in patients with advanced cancers. Proc Am Soc Clin Oncol 2003;22:Abstr 769.
8. Rosen L MM, Long J, Wittner J, Brown J, Martino AM, Bello CL, Walter S, Scigalla P, Zhu J: Phase I trial of SU011248, a novel tyrosine kinase inhibitor in advanced solid tumors. Proc Am Soc Clin Oncol 2003;22:Abstr 765.
9. Fiedler W, Serve H, Dohner H, et al.: A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 2005;105:986-93.
10. Srinivas SRJ, Gillessen S, Harmenberg U, De Mulder PH, Fountzilas G, Vogelzang N, Peschel C, Flodgren P, Escudier B: Continuous daily administration of sunitinib in patients (pts) with cytokine-refractory metastatic renal cell carcinoma (mRCC): Updated results. J Clin Oncol, ASCO Annual Meeting Proceedings Part I 2007;25:Abstr 5040.
11. George SBJ, Casali PG, Le Cesne A, DePrimo SE, Harmon CS, Law CN, Tassell V, Baum CM, Demetri GD: Continuous daily dosing (CDD) of sunitinib (SU) in pts with advanced GIST: Updated efficacy, safety, PK and pharmacodynamic analysis. J Clin Oncol 2008;26:ASCO Annual Meeting (May 20 suppl):Abstr 10554.
12. Houk BE BC, Michaelson MD, Bukowski RM, Redman BG, Hudes GR, Wilding G, Motzer RJ. Exposure-response of sunitinib in metastatic renal cell carcinoma (mRCC): A population pharmacokinetic/pharmacodynamic (PKPD) approach. J Clin Oncol, ASCO Annual Meeting Proceedings Part I 2007;25:Abstr 5027.